Using Number Needed to Harm to Put the Risk of Herpes Zoster From Tofacitinib in Perspective

Inflamm Bowel Dis. 2019 May 4;25(6):955-957. doi: 10.1093/ibd/izy387.

Authors

Freddy Caldera¹, Mary S Hayney², Raymond K Cross³

Affiliations

¹ Division of Gastroenterology and Hepatology, Department of Medicine, School of Medicine & Public Health.
² School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin.
³ Division of Gastroenterology and Hepatology, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.

PMID: 30605536
DOI: 10.1093/ibd/izy387

No abstract available

Keywords: herpes zoster; inflammatory bowel disease; infliximab; number needed to harm; tofacitinib; vedolizumab.

MeSH terms

Herpes Zoster / chemically induced*
Herpes Zoster / epidemiology*
Herpes Zoster / virology
Herpesvirus 3, Human / drug effects*
Humans
Incidence
Inflammatory Bowel Diseases / drug therapy*
Piperidines / adverse effects*
Prognosis
Protein Kinase Inhibitors / adverse effects*
Pyrimidines / adverse effects*
Pyrroles / adverse effects*
United States / epidemiology

Substances

Piperidines
Protein Kinase Inhibitors
Pyrimidines
Pyrroles
tofacitinib